MeSH note : nitroimidazopyran derived from 5-nitroimidazoles; a prodrug that requires activation
by a bacterial F420-depedent glucose-6-phosphate dehydrogenase (Fgd) and nitroreductase
to activate components that then inhibit bacterial mycolic acid and protein synthesis;
structure in first source;
https://www.ema.europa.eu/en/medicines/human/EPAR/pretomanid-fgk 2020 false false false United Kingdom French English treatment outcome syndication feed summary of product characteristics package leaflet drug evaluation drug approval europe nitroimidazoles nitroimidazoles orphan drug production tuberculosis, Drug-Resistant bedaquiline Linezolid administration, oral tuberculosis, multidrug-resistant extensively drug-resistant tuberculosis antitubercular agents antitubercular agents drug therapy, combination product surveillance, postmarketing adult drug interactions pregnancy breast feeding drugs for treatment of tuberculosis drug evaluation, preclinical pretomanid pretomanid diarylquinolines quinolines